As a consequence, the in vivo efficacy of MSC treatment against malaria was evaluated in a mouse model of P. berghei infection; administration of MSCs was found to confer host resistance against malaria through increasing IL-12 production, and suppressing IL-10 and regulatory T cell production [9]. Here, IL10 is linked to malaria.